Osiem twarzy ramiprilu, czyli drogowskaz terapeutyczny dla lekarza praktyka A.D. 2023 Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
lis 30, 2023
Słowa kluczowe:
ramipril, nadciśnienie tętnicze, ryzyko sercowo-naczyniowe, prewencja
##plugins.themes.bootstrap3.article.main##
Abstrakt
Zgodnie z aktualnymi wytycznymi przy podejmowaniu decyzji o rozpoczęciu leczenia hipotensyjnego najistotniejsze jest oszacowanie ryzyka sercowo-naczyniowego związanego ze stopniem nadciśnienia tętniczego oraz z liczbą i rodzajem współistniejących czynników ryzyka. Współczesna terapia polega bowiem nie tylko na uzyskaniu trwałej normotensji przy zachowaniu dobrej jakości życia, ale również na korygowaniu zaburzeń hemodynamicznych i metabolicznych, a przede wszystkim – na przedłużaniu życia poprzez redukcję zachorowalności i umieralności z powodu incydentów wieńcowych, niewydolności serca oraz udarów mózgu. U większości pacjentów z nadciśnieniem tętniczym i różnymi schorzeniami współistniejącymi lub wysokim ryzykiem powikłań sercowo-naczyniowych najkorzystniejszym wyborem jest lek blokujący układ renina–angiotensyna–aldosteron. W chorobie wieńcowej i innych sytuacjach wysokiego ryzyka krążeniowego szczególna rola przypada ramiprilowi, który oprócz działania hipotensyjnego wykazuje wybitne właściwości kardio- i wazoprotekcyjne.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Barylski , M. (2023). Osiem twarzy ramiprilu, czyli drogowskaz terapeutyczny dla lekarza praktyka A.D. 2023 . Medycyna Faktów , 16(3(60), 296-301. https://doi.org/10.24292/01.MF.0323.02
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Mancia G, Kreutz R, Brunström M et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023 (w druku).
2. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1-84.
3. The Heart Outcome Prevention Evaluation Study Investigators. Effect of angiotensin-converting enzyme, ramipril on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145-53.
4. HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation. 2005; 112(9): 1339-46.
5. Heart Outcomes Prevention Evaluation Study Investigators. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000; 355: 253-9.
6. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006; 355: 1551-62.
7. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993; 342: 821-8.
8. Hall AS, Murray GD, Ball SG on behalf of the AIREX Study Investigators. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet. 1997; 349: 1493-7.
9. Pfeffer MA, Greaves SC, Arnold JM et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation. 1997; 95(12): 2643-51.
10. Kjoller-Hansen L, Steffensen R, Grande P. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J Am Coll Cardiol. 2000; 35(4): 881-8.
11. Lièvre M, Guéret P, Gayet C et al. Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group. Hypertension. 1995; 25(1): 92-7.
12. Agabiti-Rosei E, Ambrosioni E, Dal Palu C et al. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (Ramipril Cardioprotective Evaluation) study on behalf of the RACE study group. J Hypertens. 1995; 13: 1325-34.
13. Lonn E, Yusuf S, Dzavik V et al.; SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001; 103(7): 919-25.
14. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999; 354: 359-64.
15. Charakterystyka produktu leczniczego Tritace, 2,5 mg, 5 mg, 10 mg, tabletki; 06.2021.
16. The ONTARGET Investigators: Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 1547-59.
17. Szczepańska-Sadowska E, Cudnoch-Jędrzejewska A. Fizjologia i patofizjologia układu renina–angiotensyna. In: Januszewicz A, Januszewicz W, Rużyłło W (ed). Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Medycyna Praktyczna, Kraków 2005: 23-62.
18. Enseleit F, Lüscher TF, Ruschitzka F. Angiotensin-converting enzyme inhibition and endothelial dysfunction: focus on ramipril. Eur Heart J. 2003 (suppl A); 5: A31-A36.
19. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362(9386): 782-8.
20. Borghi C, Ambrosioni E, Novo S et al. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel group, multicenter, European study (SMILE-4). Clin Cardiol. 2012; 35: 416-23.
21. Braunwald E, Domanski MJ, Fowler SE et al.; PEACE Trial Investigators: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004; 351(20): 2058-68.
22. Rouleau JL, Warnica WJ, Baillot R et al.; IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators: Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation. 2008; 117(1): 24-31.
23. Wienbergen H, Schiele R, Gitt AK et al.; MITRA PLUS Study Group: Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. Am J Cardiol. 2002; 90(10): 1045-9.
24. Mathew J, Sleight P, Lonn E et al.; Heart Outcomes Prevention Evaluation (HOPE) Investigators: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001; 104(14): 1615-21.
25. Cleland JG, Erhardt L, Murray G et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J. 1997; 18(1): 41-51.
2. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1-84.
3. The Heart Outcome Prevention Evaluation Study Investigators. Effect of angiotensin-converting enzyme, ramipril on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145-53.
4. HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation. 2005; 112(9): 1339-46.
5. Heart Outcomes Prevention Evaluation Study Investigators. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000; 355: 253-9.
6. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006; 355: 1551-62.
7. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993; 342: 821-8.
8. Hall AS, Murray GD, Ball SG on behalf of the AIREX Study Investigators. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet. 1997; 349: 1493-7.
9. Pfeffer MA, Greaves SC, Arnold JM et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation. 1997; 95(12): 2643-51.
10. Kjoller-Hansen L, Steffensen R, Grande P. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J Am Coll Cardiol. 2000; 35(4): 881-8.
11. Lièvre M, Guéret P, Gayet C et al. Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group. Hypertension. 1995; 25(1): 92-7.
12. Agabiti-Rosei E, Ambrosioni E, Dal Palu C et al. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (Ramipril Cardioprotective Evaluation) study on behalf of the RACE study group. J Hypertens. 1995; 13: 1325-34.
13. Lonn E, Yusuf S, Dzavik V et al.; SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001; 103(7): 919-25.
14. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999; 354: 359-64.
15. Charakterystyka produktu leczniczego Tritace, 2,5 mg, 5 mg, 10 mg, tabletki; 06.2021.
16. The ONTARGET Investigators: Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 1547-59.
17. Szczepańska-Sadowska E, Cudnoch-Jędrzejewska A. Fizjologia i patofizjologia układu renina–angiotensyna. In: Januszewicz A, Januszewicz W, Rużyłło W (ed). Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Medycyna Praktyczna, Kraków 2005: 23-62.
18. Enseleit F, Lüscher TF, Ruschitzka F. Angiotensin-converting enzyme inhibition and endothelial dysfunction: focus on ramipril. Eur Heart J. 2003 (suppl A); 5: A31-A36.
19. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362(9386): 782-8.
20. Borghi C, Ambrosioni E, Novo S et al. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel group, multicenter, European study (SMILE-4). Clin Cardiol. 2012; 35: 416-23.
21. Braunwald E, Domanski MJ, Fowler SE et al.; PEACE Trial Investigators: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004; 351(20): 2058-68.
22. Rouleau JL, Warnica WJ, Baillot R et al.; IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators: Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation. 2008; 117(1): 24-31.
23. Wienbergen H, Schiele R, Gitt AK et al.; MITRA PLUS Study Group: Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. Am J Cardiol. 2002; 90(10): 1045-9.
24. Mathew J, Sleight P, Lonn E et al.; Heart Outcomes Prevention Evaluation (HOPE) Investigators: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001; 104(14): 1615-21.
25. Cleland JG, Erhardt L, Murray G et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J. 1997; 18(1): 41-51.